262 related articles for article (PubMed ID: 16932807)
1. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.
McMahan RH; McWilliams JA; Jordan KR; Dow SW; Wilson DB; Slansky JE
J Clin Invest; 2006 Sep; 116(9):2543-51. PubMed ID: 16932807
[TBL] [Abstract][Full Text] [Related]
2. Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.
Buhrman JD; Jordan KR; Munson DJ; Moore BL; Kappler JW; Slansky JE
J Biol Chem; 2013 Nov; 288(46):33213-25. PubMed ID: 24106273
[TBL] [Abstract][Full Text] [Related]
3. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
4. Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Wei P; Jordan KR; Buhrman JD; Lei J; Deng H; Marrack P; Dai S; Kappler JW; Slansky JE; Yin L
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34074778
[TBL] [Abstract][Full Text] [Related]
5. Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library.
Crawford F; Huseby E; White J; Marrack P; Kappler JW
PLoS Biol; 2004 Apr; 2(4):E90. PubMed ID: 15094798
[TBL] [Abstract][Full Text] [Related]
6. Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.
Buhrman JD; Jordan KR; U'ren L; Sprague J; Kemmler CB; Slansky JE
Cancer Res; 2013 Jan; 73(1):74-85. PubMed ID: 23161490
[TBL] [Abstract][Full Text] [Related]
7. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.
Jordan KR; McMahan RH; Kemmler CB; Kappler JW; Slansky JE
Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4652-7. PubMed ID: 20133772
[TBL] [Abstract][Full Text] [Related]
8. Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen.
Zhou S; Song Y; Luo Y; Quinn B; Jiao Y; Long MD; Abrams SI; Lovell JF
Cancer Res Commun; 2024 Apr; 4(4):958-969. PubMed ID: 38506662
[TBL] [Abstract][Full Text] [Related]
9. Is TCR/pMHC Affinity a Good Estimate of the T-cell Response? An Answer Based on Predictions From 12 Phenotypic Models.
Gálvez J; Gálvez JJ; García-Peñarrubia P
Front Immunol; 2019; 10():349. PubMed ID: 30886616
[TBL] [Abstract][Full Text] [Related]
10. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex.
Kalergis AM; Boucheron N; Doucey MA; Palmieri E; Goyarts EC; Vegh Z; Luescher IF; Nathenson SG
Nat Immunol; 2001 Mar; 2(3):229-34. PubMed ID: 11224522
[TBL] [Abstract][Full Text] [Related]
11. Modulation of T cell function by TCR/pMHC binding kinetics.
Carreño LJ; González PA; Kalergis AM
Immunobiology; 2006; 211(1-2):47-64. PubMed ID: 16446170
[TBL] [Abstract][Full Text] [Related]
12. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.
Dutoit V; Guillaume P; Cerottini JC; Romero P; Valmori D
Eur J Immunol; 2002 Nov; 32(11):3285-93. PubMed ID: 12555674
[TBL] [Abstract][Full Text] [Related]
13. Estimation of maximal affinities between T-cell receptors and MHC/peptide complexes.
Salzmann M; Bachmann MF
Mol Immunol; 1998 Feb; 35(2):65-71. PubMed ID: 9683252
[TBL] [Abstract][Full Text] [Related]
14. Mimotopes of tumor-associated T-cell epitopes for cancer vaccines determined with combinatorial peptide libraries.
Sherev T; Wiesmüller KH; Walden P
Mol Biotechnol; 2003 Sep; 25(1):53-61. PubMed ID: 13679635
[TBL] [Abstract][Full Text] [Related]
15. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection.
Speiser DE; Kyburz D; Stübi U; Hengartner H; Zinkernagel RM
J Immunol; 1992 Aug; 149(3):972-80. PubMed ID: 1634779
[TBL] [Abstract][Full Text] [Related]
16. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
Lustgarten J; Waks T; Eshhar Z
Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
[TBL] [Abstract][Full Text] [Related]
17. Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.
Spear TT; Wang Y; Foley KC; Murray DC; Scurti GM; Simms PE; Garrett-Mayer E; Hellman LM; Baker BM; Nishimura MI
Cancer Immunol Immunother; 2017 Nov; 66(11):1411-1424. PubMed ID: 28634816
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
[TBL] [Abstract][Full Text] [Related]
19. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR.
al-Ramadi BK; Jelonek MT; Boyd LF; Margulies DH; Bothwell AL
J Immunol; 1995 Jul; 155(2):662-73. PubMed ID: 7541822
[TBL] [Abstract][Full Text] [Related]
20. Stress-testing the relationship between T cell receptor/peptide-MHC affinity and cross-reactivity using peptide velcro.
Gee MH; Sibener LV; Birnbaum ME; Jude KM; Yang X; Fernandes RA; Mendoza JL; Glassman CR; Garcia KC
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7369-E7378. PubMed ID: 30021852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
